Cutaneous melanoma - Diagnostic and therapeutic guidelines in 2013;Czerniaki skóry - zasady postępowania diagnostyczno- terapeutycznego w 2013 roku

Przeglad Dermatologiczny

Volumn 100, Issue 1, 2013, Pages 1-15

  Rutkowski, Piotr ^a   Wysocki, Piotr J ^b   Nowecki, Zbigniew I ^a   Rudnicka, Lidia ^c   Nasierowska Guttmejer, Anna ^c   Fijuth, Jacek ^d   Kalinka Warzocha, Ewa ^d   Świtaj, Tomasz ^a   Wojtukiewicz, Marek ^e   Zegarski, Wojciech ^f   Jeziorski, Arkadiusz ^d   Krzemieniecki, Krzysztof ^g   Zaucha, Renata ^h   Filipczyk Cisarz, Emilia ⁱ   Herman, Krzysztof ^j   Krzakowski, Maciej ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Centralny Szpital Kliniczny MSW w Warszawie   (Poland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^f NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^j INSTITUTE OF ONCOLOGY   (Poland)

more..

Author keywords

Dermoscopy; Diagnosis; Melanoma; Nevi; Therapy

Indexed keywords

B RAF KINASE; DACARBAZINE; IPILIMUMAB; VEMURAFENIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CUTANEOUS MELANOMA; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; DRUG EFFICACY; DRUG INDICATION; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS RESECTION; PATIENT PARTICIPATION; PRACTICE GUIDELINE; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN SURGERY; SURVIVAL TIME;

EID: 84875909982     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rutkowski P. (red.). Złośliwe nowotwory skóry. Via Medica, Gdańsk 2011.
2. Didkowska J., Wojciechowska U., Tarkowski W., Zatoński W.: Nowotwory złośliwe w Polsce w 2009 roku. Centrum Onkologii-Instytut, Warszawa, 2011.
3. Ruka W., Krzakowski M., Placek W., Rutkowski P., Nowecki Z.I., Fijuth J. i inni: Czerniaki skóry - zasady poste{ogonek}powania diagnostyczno-terapeutycznego. Onkol Prakt Klin 2009, 5, 20-32.
4. Dummer R., Hauschild A., Guggenheim M., Keilholz U., Pentheroudakis G; ESMO Guidelines Working Group: Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23 (suppl 7).
5. NCCN Guidelines. Melanoma version 1.2013.
6. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R. i inni: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27, 6199-6206.
7. Morton D.L., Thompson J.F., Ochran A.J., Mozzillo N., Elashoff R., Essner R. i inni: Sentinel-node biopsy or nodal observation in melanoma. NEJM 2006; 355: 1307-1317.
8. Wong S.L., Balch C.M., Hurley P., Agarwala S.S., Ak -hurst T.J., Cochran A. i inni: American Society of Clinical Oncology; Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012, 30, 2912-2918.
9. Nowecki Z.I., Rutkowski P., Michej W.: The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol 2008, 15, 2223-2234.
10. van Akkooi A.C.J., Nowecki Z.I., Voit C., Schaefer-Hesterberg G., Michej W., de Wilt J.H.W. i inni: Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008, 248, 949-955.
11. Testori A., Rutkowski P., Marsden J., Bastholt L., Chiarion-Sileni V., Hauschild A. i inni: Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 2009, 20 (suppl 6), 22-29.
12. Eggermont A.M.M., Gore M.: Randomized adjuvant therapy trials in melanoma: surgical and systemic. Sem Oncol 2007, 34, 509-515.
13. Sondak V.K., Gonzalez R.J., Kudchadkar R.: Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am 2011, 20, 105-114.
14. Eggermont A.M., Suciu S., Testori A., Kruit W.H., Marsden J., Punt CJ i inni: Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012, 48, 218-225.
15. Burmeister B.H., Henderson M.A., Ainslie J., Fisher R., Di Iulio J., Smithers B.M. i inni: Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012, 13, 589-597.
16. Ballo M.T., Ang K.K.: Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology 2004, 18, 99-107.
17. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B. i inni: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 19, 363, 711-723.
18. Świtaj T., Wysocki P., Wojtukiewicz M., Potemski P., Rudnicka L., Bartnik W. i inni: Ipilimumab - poste{ogonek}p w terapii chorych na zaawansowanego czerniaka. Onkol Prakt Klin 2011, 7, 231-245.
19. Wolchok J.D., Hoos A., O'Day S.J., Weber J.S., Hamid O., Lebbé C. i inni: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15, 7412-7420.
20. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J. i inni: BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364, 2507-2516.
21. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M. i inni: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380, 358-365.
22. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M. i inni: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367, 107-114.
23. Ascierto P.A., Berking C., Agarwala S.S., Schadendorf D., Van Herpen C., Queirolo P. i inni: Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 2012, 30 (suppl), Abstract 8511.
24. Guo J., Si L., Kong Y., Flaherty K.T., Xu X., Zhu Y. i inni: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011, 29, 2904-2909.